Tools
Foster Kennedy Syndrome
Introduction
Foster Kennedy syndrome (FKS) is based on neurological signs characterized by anosmia and vision loss (central scotoma), which may be unilateral or bilateral depending on the stage of the condition. It is defined by compressive optic damage (atrophy) in one eye and contralateral papilledema, resulting from increased intracranial pressure secondary to an intracranial space-occupying lesion.[1]
It is worth noting that the classic presentation of FKS is also found in pseudo-FKS; thus, it is of utmost importance that the attending clinician is astute in selecting and carrying out the proper examination techniques to provide an accurate diagnosis.
There are typically three types of FKS.[2] Type 1, the most frequent form, presents with optic atrophy in the ipsilateral eye and papilledema in the contralateral eye. Type 2 is characterized by bilateral papilledema and unilateral optic atrophy.[3] Type 3 is defined by bilateral papilledema developing into bilateral optic atrophy. The three types of FKS are caused by different stages of metastasis of brain tumors.
Pseudo-FKS has the typical presentation of optic atrophy in one eye and papilledema in the contralateral eye, similar to type 1 FKS.[4] However, there is no underlying compressive pathology in pseudo-FKS.[5][6] Causes of pseudo-FKS include optic nerve compression by the gyrus rectus, diabetic papillopathy, and unilateral optic nerve hypoplasia.[7][8]
Meningiomas (See Figures of computerized tomography scans of frontal-temporal meningioma and frontal-sphenoidal meningioma) are space-occupying tumors originating in the central nervous system.[9] The term refers to specific disorders of the pia, dura, and arachnoid layers encapsulating the brain. They can either be cancerous or non-cancerous.[10] The common sites for occurrence include the sphenoid wing, olfactory groove, and frontal lobe.[11][12]
Meningiomas are the most common type of non-malignant tumors found in the brain.[13] Meningiomas are often insidious in progression, leading to subtle progressive changes that may go unnoticed as the condition progresses. They may initially herniate into the subarachnoid space and dural sinuses leading to intracranial hypertension. Meningiomas eventually compress on adjacents vessels and sections of the brain, causing an array of symptoms and eventual tissue atrophy.
Tumors of the pituitary gland have also been reported to cause FKS and are the second-highest cause of cerebral tumors.[14][15] This risk becomes exacerbated in patients who have undergone surgical resection for pituitary adenomas and radiotherapy as they may subsequently develop complications, including tentorial meningiomas.[16][17][18]
Etiology
Register For Free And Read The Full Article
Search engine and full access to all medical articles- 10 free questions in your specialty
- Free CME/CE Activities
- Free daily question in your email
- Save favorite articles to your dashboard
- Emails offering discounts
Learn more about a Subscription to StatPearls Point-of-Care
Etiology
Brain tumors account for about 12% of optic disc swelling.[19] The mass-causing lesion is usually an anterior cranial fossa meningioma. However, tumors in other parts of the brain like the frontal lobe, olfactory groove, sphenoid wing, and pituitary gland can also cause the condition (See Figures of computerized tomography scans of frontal-temporal meningioma and frontal-sphenoidal meningioma).[15][8]
Risk factors for meningiomas include hereditary factors, female hormones, and prior radiation exposure.[20] These tumors compress on the optic nerve on the ipsilateral side of the brain in which they are formed, causing progressive optic atrophy. As they grow larger, they may breach the cerebral falx and cross over to the contralateral side, causing a restricted flow of the cerebrospinal fluid and papilledema in that eye. Alternatively, a patient may present with complete optic atrophy in one eye and temporal hemianopsia in the other eye.[15]
Epidemiology
Studies have shown the age-adjusted incidence rate of central nervous system tumors to be 23.41 per 100,000 individuals.[13] The reported rates were slightly higher in females.[20] FKS has been reported in 1 to 2.5% of intracranial tumors.[21]
Pathophysiology
Foster Kennedy syndrome forms due to intracranial space-occupying lesions (ICSOL), especially those in the anterior cranial fossa. The presence of the ICSOL causes an increase in intracranial pressure and direct compression of the nerve, which results in ipsilateral optic atrophy due to the death of nerve fibers, considering that the nerve fiber swelling is usually not noticed in the limited fibers remaining after the damage.
The increased intracranial pressure causes the swelling of the optic disc of the contralateral eye, which still has enough nerve fibers that make swelling evident. The anosmia is a result of the ICSOL compressing the olfactory nerve.
History and Physical
When discussing signs and anamnesis with patients, it is important to note complaints of headaches, unilateral or bilateral reduction in vision, and anosmia in some cases (later stages of the condition). The clinician can expect to see an elevated optic disc (papilledema; detection of papilledema can be tricky at the early stages, especially in stage 1 papilledema, which may show a C-shaped halo with preservation of the temporal margin of the disc).
The later stages of the sign papilledema are more easily identifiable due to the elevation of the disc with obscured blood vessels. These more advanced stages of papilledema can be correlated with signs of a tumor in the forebrain, including emotional lability, difficulties in moving/uncoordinated movement, and a speech impediment. ICSOL of the forebrain can extend beyond the anterior cranial fossa and, as such, present with other associated tumors affecting other parts of the brain.
Evaluation
The initial evaluation of Foster Kennedy syndrome is usually via a funduscopy, preferably dilated. Ophthalmoscopy, slit-lamp biomicroscopy with an accessory lens or fundus imagery allows the examiner to visualize the back of the eye. Visualization of optic atrophy and damage to the retinal nerve fiber layer is enhanced with a red-free filter. Papilledema is best assessed by directly viewing the optic disc using a slit aperture during ophthalmoscope, which is a typical feature in FKS.[22]
Radiologic imaging may precede or follow ocular examination depending on the flow of patient care. Standard X-rays are not very useful in detecting brain tumors because the skull absorbs the radiation, thus preventing deeper tissue viewing.
Literature shows a positive correlation between raised intracranial pressure and increased intraocular pressure. Intraocular pressure can be measured by contact or non–contact tonometry.[23][24]
Computerized tomography (CT) scans use X-rays emitted through different body parts combined with a computer algorithm to generate scans of slices of the part of the body being imaged. The patient should be advised to minimize movement during the procedure for optimum image quality. Metals, reflective objects, and clothing should also be removed from the head before imaging. The patient usually lies prone on an electronic bed while the equipment takes multiple scans as it rotates around the body. An iodine-based contrast agent may be injected into the patient’s vein to give even better scan images.[25]
It is important to ensure an appropriate kidney function testing is done to ensure the patient can eliminate the agent after administration.[26][27][28] A CT scan is contraindicated in pregnant individuals and requires skilled interpretation to make a proper diagnosis.[29] A CT scan tends to be fast and accurate in assisting in the differential diagnosis in patients with FKS.[30][31]
Magnetic resonance imaging (MRI) provides more enhanced images than a CT scan. In addition, it does use ionizing radiation and is therefore safer. MRI uses a magnetic field to disrupt the random arrangement of atoms in the body into a systematic arrangement.[32] The equipment then sends a radio wave that excites these atoms from their new position. When this radio wave is turned off, the atoms return to their initial position, giving off a radio signal in the process.[33]
An embedded algorithm in the MRI equipment then converts these emitted signals into a two-dimensional image of the part of the body being observed.[34] Because of the absence of ionizing radiation, an MRI is the scan of choice used when monitoring the progression of a brain mass/tumor.[35][36]
This type of testing takes longer than CT scans, which can seldom be performed in emergency patients in most hospitals; thus needs to be booked and tends to come after the acquisition of CT scans in most patients with FKS.
Treatment / Management
The treatment modality for Foster Kennedy syndrome tumors include:
- Surgical resection
- Chemotherapy
- Radiotherapy
- Medical therapy
The management of FKS is usually by surgical resection, although chemotherapy and radiotherapy are also employed, especially in old geriatric patients who are more prone to mortality.[37][38]
Regarding medical therapy, the first line of action is to give systemic corticosteroids, although it is usually an asymptomatic treatment for the reduction of edema around the tumor and intracranial pressure.[39]
In older patients, it is preferable to go for a non-neurosurgical procedure such as stereotactic radiotherapy and radiosurgery. The use of hydroxyurea has been anecdotally found to be useful, especially for unresectable tumors and large residual tumors.[40](B3)
Differential Diagnosis
The differential diagnosis of Foster Kennedy syndrome include:
- Frontal lobe parenchyma tumors
- Meningioma (e.g., olfactory, frontal, sphenoid wing)
- Pseudo-FKS
- Non-arteritic anterior ischemic optic neuropathy (NAION)
- Optic nerve hypoplasia
- Optic neuritis
- Vitamin B12 deficiency
Tumors that affect the frontal lobe are included in the differential diagnosis of FKS, especially those affecting brain structure in the anterior cranial fossa. Tumors of the brain meninges, i.e., those involving the olfactory, frontal lobe, and sphenoid wing, need to be considered. These tumors can occur without ocular complications and would therefore not qualify as FKS.
Pseudo-FKS is the most common differential diagnosis of FKS; simplifying its definition, one can say pseudo-FKS is FKS without a tumor.[1] Pseudo-FKS can mimic FKS, but the clinical features and presentation are different. One fundamental difference is the absence of tumors, which means less emotional or intelligence lability.
NAION is the second highest cause of optic neuropathy. It is a condition of non-inflammatory ischemia of the 1mm region of the optic disc typically due to the reduction in blood flow through the posterior ciliary artery, which supplies the optic nerve head (anterior part of the optic nerve). It has been suggested to be caused by embolism. It can also be caused by a nocturnal drop in perfusion pressure.[41]
Optic nerve hypoplasia is a congenital condition in which the optic nerve does not develop fully, thus giving the classic small and pale appearance of the optic nerve. There are cases where optic nerve hypoplasia is seen together with NAION.[8] The causes have not been clearly understood, but there have been correlational studies showing the relationship between optic nerve hypoplasia and fetal alcohol syndrome in addition to maternal intake of quinine, phenytoin, and lysergic acid diethylamide.
Optic neuritis is the inflammation of the optic nerve and is called optic papillitis when it involves the optic nerve head. It is called neuro-retinitis when it involves the optic nerve head and the macula. It is termed retrobulbar neuritis when it involves the posterior part of the nerve.[42]
Papilledema is a sign of a pathologic condition in the eye presenting as an elevation of the optic nerve head. It results from a sustained increase in the intracranial pressure with varying degrees of blurred optic disc margin and reduction.
Vitamin B12 deficiency can also result in progressive optic neuropathy, masquerading as FKS. This condition is, however, reversible with appropriate supplements.[43]
Surgical Oncology
The decision to proceed to surgery for Foster Kennedy syndrome depends on a risk-benefit analysis as recommended by the consulting physicians. Brain surgery is a multi-disciplinary decision and procedure. As with all tumors, complete removal of the cancer is recommended in the event of surgical intervention. Tissue samples should be sent for a histopathological examination for a better understanding and staging of the lesion. Surgery can be followed by adjuvant chemotherapy.[38][40]
Radiation Oncology
Radiotherapy is recommended as an adjunct treatment to surgery and for people with recurrent tumors.[44] While some authors recommend radiotherapy immediately, others advise using radiotherapy later if the lesion shows signs of progression and/or recurrence.[45][46]
Prognosis
The prognosis of Foster Kennedy syndrome is determined mainly by the location, size, and stage of the causative ICSOL.
Complications
Complications from Foster Kennedy syndrome can either be ocular or systemic. Ocular complications of FKS include disc edema, relative afferent pupillary defects, restriction in ocular movements, decreased visual acuity, papilledema, and optic atrophy.[21]
Systemic complications include anosmia and all other symptoms that may arise from a tumor compressing specific brain areas.
Deterrence and Patient Education
Foster Kennedy syndrome can sometimes be the first signs and symptoms that initiate further investigations and examinations, which provide the diagnosis of a brain tumor. It is important to inform the patient of the necessity of a multidisciplinary approach to correctly manage the disease to address issues related to the quality of life, treatment, and prognosis.
Enhancing Healthcare Team Outcomes
Eye care providers must be able to detect conditions like optic atrophy and papilledema, as this may be the first opportunity to diagnose a much more severe disease. Clinicians who suspect FKS in a patient must immediately send for detailed brain scans to localize the location of the ICSOL.
The results of these scans can direct neurosurgeons on the best route of action. While clinicians tend to prefer surgery as first-line treatment, chemotherapy and radiotherapy have also shown promising results in some patients. As with all tumors, the risk of metastasis and multiple organ involvement is always possible. FKS patients must be appropriately counseled on management, treatment options, quality of life, the likely prognosis, risks of metastasis, and fatality of the disease.
Interprofessional teamwork involves clinicians and nursing staff, and when medical management is part of the picture, pharmacists are important in optimizing care for patients with FKS. ALl te4am members must be diligent in documenting their findings, monitoring patient progress, contributing from their area of expertise, and keeping all other interprofessional team members informed of any status changes so corrective action can be implemented if necessary. This interprofessional approach will yield the best possible outcomes. [Level 5]
Media
(Click Image to Enlarge)
Computerized tomography scans of a frontal-temporal meningioma in a 30-year-old black female patient with Foster Kennedy syndrome (FKS). Contributed by Mutali Musa, OD.
(Click Image to Enlarge)
Computerized tomography scans of frontal-sphenoidal meningioma in 52-year-old black male patient with Foster Kennedy syndrome (FKS). Contributed by Mutali Musa, OD.
References
Hata M, Miyamoto K. Causes and Prognosis of Unilateral and Bilateral Optic Disc Swelling. Neuro-ophthalmology (Aeolus Press). 2017 Aug:41(4):187-191. doi: 10.1080/01658107.2017.1299766. Epub 2017 Apr 10 [PubMed PMID: 29344057]
Eidet JR, Biernat D, Dahlberg D, Wiedmann MKH, Jørstad ØK. [Foster Kennedy Syndrome]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke. 2019 Jun 25:139(10):. doi: 10.4045/tidsskr.18.0719. Epub 2019 Jun 24 [PubMed PMID: 31238653]
Zehden J, Harish Bindiganavile S, Bhat N, Lee AG. Compressive Optic Disc Edema and Contralateral Papilledema: Type 2 Foster Kennedy Variant Syndrome. Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society. 2021 Jun 1:41(2):e217-e219. doi: 10.1097/WNO.0000000000001091. Epub [PubMed PMID: 33105415]
David C, Suvac E, Tăbăcaru B, Stanca TH. Pseudo-Foster Kennedy Syndrome - a case report. Romanian journal of ophthalmology. 2016 Oct-Dec:60(4):270-274 [PubMed PMID: 29450361]
Level 3 (low-level) evidenceMicieli JA, Al-Obthani M, Sundaram AN. Pseudo-Foster Kennedy syndrome due to idiopathic intracranial hypertension. Canadian journal of ophthalmology. Journal canadien d'ophtalmologie. 2014 Aug:49(4):e99-e102. doi: 10.1016/j.jcjo.2014.05.002. Epub 2014 Jul 16 [PubMed PMID: 25103671]
Level 3 (low-level) evidenceVisa Reñé N, Paredes Carmona F. Pseudo-Foster Kennedy syndrome due to idiopathic intracranial hypertension. Archivos de la Sociedad Espanola de Oftalmologia. 2019 Dec:94(12):598-601. doi: 10.1016/j.oftal.2019.09.006. Epub 2019 Oct 18 [PubMed PMID: 31635921]
Desai N, Yong RL, Doshi A, Rucker JC. Pseudo-Foster-Kennedy syndrome with optic nerve compression by the gyrus rectus. Neurology. 2015 Jul 28:85(4):385. doi: 10.1212/WNL.0000000000001791. Epub [PubMed PMID: 26215878]
Bansal S, Dabbs T, Long V. Pseudo-Foster Kennedy Syndrome due to unilateral optic nerve hypoplasia: a case report. Journal of medical case reports. 2008 Mar 18:2():86. doi: 10.1186/1752-1947-2-86. Epub 2008 Mar 18 [PubMed PMID: 18348732]
Level 3 (low-level) evidenceOgasawara C, Philbrick BD, Adamson DC. Meningioma: A Review of Epidemiology, Pathology, Diagnosis, Treatment, and Future Directions. Biomedicines. 2021 Mar 21:9(3):. doi: 10.3390/biomedicines9030319. Epub 2021 Mar 21 [PubMed PMID: 33801089]
Level 3 (low-level) evidenceBuerki RA, Horbinski CM, Kruser T, Horowitz PM, James CD, Lukas RV. An overview of meningiomas. Future oncology (London, England). 2018 Sep:14(21):2161-2177. doi: 10.2217/fon-2018-0006. Epub 2018 Aug 7 [PubMed PMID: 30084265]
Level 3 (low-level) evidenceZhang J, Sai K, Zhu ZQ, Lin FH, Wang ZF, Chen YM, Huang CY, Ye YL, Wang XL, Li YP, Sun SX, Zhong WY, Chen JB, Yang YQ. Prognostic factors for olfactory groove meningioma with nasal cavity extension. Oncotarget. 2018 Jan 12:9(4):4607-4613. doi: 10.18632/oncotarget.23461. Epub 2017 Dec 19 [PubMed PMID: 29435128]
Sun C, Dou Z, Wu J, Jiang B, Iranmanesh Y, Yu X, Li J, Zhou H, Zhong C, Peng Y, Zhuang J, Yu Q, Wu X, Yan F, Xie Q, Chen G. The Preferred Locations of Meningioma According to Different Biological Characteristics Based on Voxel-Wise Analysis. Frontiers in oncology. 2020:10():1412. doi: 10.3389/fonc.2020.01412. Epub 2020 Aug 21 [PubMed PMID: 32974148]
Ostrom QT, Cioffi G, Gittleman H, Patil N, Waite K, Kruchko C, Barnholtz-Sloan JS. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016. Neuro-oncology. 2019 Nov 1:21(Suppl 5):v1-v100. doi: 10.1093/neuonc/noz150. Epub [PubMed PMID: 31675094]
Gatto F, Perez-Rivas LG, Olarescu NC, Khandeva P, Chachlaki K, Trivellin G, Gahete MD, Cuny T, on behalf of the ENEA Young Researchers Committee (EYRC). Diagnosis and Treatment of Parasellar Lesions. Neuroendocrinology. 2020:110(9-10):728-739. doi: 10.1159/000506905. Epub 2020 Mar 4 [PubMed PMID: 32126547]
Ayele B, Mengesha A, Wotiye A, Alemayehu Y. Giant Pituitary Adenoma Presenting with Foster-Kennedy Syndrome in a 21-Year Old Ethiopian Patient: A Rarely Reported Phenomenon: A Case Report. Ethiopian journal of health sciences. 2020 Mar:30(2):311-314. doi: 10.4314/ejhs.v30i2.19. Epub [PubMed PMID: 32165821]
Level 3 (low-level) evidenceSantoro A, Minniti G, Paolini S, Passacantilli E, Missori P, Frati A, Cantore GP. Atypical tentorial meningioma 30 years after radiotherapy for a pituitary adenoma. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 2002 Mar:22(6):463-7 [PubMed PMID: 11976979]
Level 3 (low-level) evidenceShashidhar A, Arimappamagan A, Madhusudhan N, Narasinga Rao KVL, Bhat D, Shukla D, Arvinda HR, Srinivas D, Indira Devi B, Somanna S. Transcranial approach for pituitary adenomas - An evaluation of surgical approaches over two decades and factors influencing peri-operative morbidity. Clinical neurology and neurosurgery. 2021 Jan:200():106400. doi: 10.1016/j.clineuro.2020.106400. Epub 2020 Dec 5 [PubMed PMID: 33341089]
Wadud SA, Ahmed S, Choudhury N, Chowdhury D. Evaluation of ophthalmic manifestations in patients with intracranial tumours. Mymensingh medical journal : MMJ. 2014 Apr:23(2):268-71 [PubMed PMID: 24858153]
Level 2 (mid-level) evidenceOsaguona VB, Kayoma DH. Etiology of Optic Disc Swelling in a Tertiary Care Center in Nigeria. Nigerian journal of clinical practice. 2020 Dec:23(12):1690-1694. doi: 10.4103/njcp.njcp_333_20. Epub [PubMed PMID: 33355822]
Sun T, Plutynski A, Ward S, Rubin JB. An integrative view on sex differences in brain tumors. Cellular and molecular life sciences : CMLS. 2015 Sep:72(17):3323-42. doi: 10.1007/s00018-015-1930-2. Epub 2015 May 19 [PubMed PMID: 25985759]
Pastora-Salvador N, Peralta-Calvo J. Foster Kennedy syndrome: papilledema in one eye with optic atrophy in the other eye. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. 2011 Dec 13:183(18):2135. doi: 10.1503/cmaj.101937. Epub 2011 Sep 26 [PubMed PMID: 21948724]
Level 3 (low-level) evidenceKotecha M, Gotecha S, Chugh A, Punia P. Neuroophthalmic Manifestations of Intracranial Tumours in Children. Case reports in ophthalmological medicine. 2021:2021():7793382. doi: 10.1155/2021/7793382. Epub 2021 May 15 [PubMed PMID: 34055437]
Level 3 (low-level) evidenceBrusini P, Salvetat ML, Zeppieri M. How to Measure Intraocular Pressure: An Updated Review of Various Tonometers. Journal of clinical medicine. 2021 Aug 27:10(17):. doi: 10.3390/jcm10173860. Epub 2021 Aug 27 [PubMed PMID: 34501306]
Li Z, Yang Y, Lu Y, Liu D, Xu E, Jia J, Yang D, Zhang X, Yang H, Ma D, Wang N. Intraocular pressure vs intracranial pressure in disease conditions: a prospective cohort study (Beijing iCOP study). BMC neurology. 2012 Aug 3:12():66 [PubMed PMID: 22862817]
Level 2 (mid-level) evidenceSolbak MS, Henning MK, England A, Martinsen AC, Aaløkken TM, Johansen S. Impact of iodine concentration and scan parameters on image quality, contrast enhancement and radiation dose in thoracic CT. European radiology experimental. 2020 Sep 11:4(1):57. doi: 10.1186/s41747-020-00184-z. Epub 2020 Sep 11 [PubMed PMID: 32915405]
Level 2 (mid-level) evidenceIyer VR, Ehman EC, Khandelwal A, Wells ML, Lee YS, Weber NM, Johnson MP, Yu L, McCollough CH, Fletcher JG. Image quality in abdominal CT using an iodine contrast reduction algorithm employing patient size and weight and low kV CT technique. Acta radiologica (Stockholm, Sweden : 1987). 2020 Sep:61(9):1186-1195. doi: 10.1177/0284185119898655. Epub 2020 Jan 27 [PubMed PMID: 31986894]
Level 2 (mid-level) evidenceSohn SY, Choi JH, Kim NK, Joung JY, Cho YY, Park SM, Kim TH, Jin SM, Bae JC, Lee SY, Chung JH, Kim SW. The impact of iodinated contrast agent administered during preoperative computed tomography scan on body iodine pool in patients with differentiated thyroid cancer preparing for radioactive iodine treatment. Thyroid : official journal of the American Thyroid Association. 2014 May:24(5):872-7. doi: 10.1089/thy.2013.0238. Epub 2014 Mar 6 [PubMed PMID: 24295076]
Level 2 (mid-level) evidenceHo JD, Tsang JF, Scoggan KA, Leslie WD. Urinary Iodine Clearance following Iodinated Contrast Administration: A Comparison of Euthyroid and Postthyroidectomy Subjects. Journal of thyroid research. 2014:2014():580569. doi: 10.1155/2014/580569. Epub 2014 Nov 12 [PubMed PMID: 25478285]
Power SP, Moloney F, Twomey M, James K, O'Connor OJ, Maher MM. Computed tomography and patient risk: Facts, perceptions and uncertainties. World journal of radiology. 2016 Dec 28:8(12):902-915. doi: 10.4329/wjr.v8.i12.902. Epub [PubMed PMID: 28070242]
Walter FM, Penfold C, Joannides A, Saji S, Johnson M, Watts C, Brodbelt A, Jenkinson MD, Price SJ, Hamilton W, Scott SE. Missed opportunities for diagnosing brain tumours in primary care: a qualitative study of patient experiences. The British journal of general practice : the journal of the Royal College of General Practitioners. 2019 Apr:69(681):e224-e235. doi: 10.3399/bjgp19X701861. Epub 2019 Mar 11 [PubMed PMID: 30858332]
Level 2 (mid-level) evidenceZienius K, Chak-Lam I, Park J, Ozawa M, Hamilton W, Weller D, Summers D, Porteous L, Mohiuddin S, Keeney E, Hollingworth W, Ben-Shlomo Y, Grant R, Brennan PM. Direct access CT for suspicion of brain tumour: an analysis of referral pathways in a population-based patient group. BMC family practice. 2019 Aug 20:20(1):118. doi: 10.1186/s12875-019-1003-y. Epub 2019 Aug 20 [PubMed PMID: 31431191]
Grover VP, Tognarelli JM, Crossey MM, Cox IJ, Taylor-Robinson SD, McPhail MJ. Magnetic Resonance Imaging: Principles and Techniques: Lessons for Clinicians. Journal of clinical and experimental hepatology. 2015 Sep:5(3):246-55. doi: 10.1016/j.jceh.2015.08.001. Epub 2015 Aug 20 [PubMed PMID: 26628842]
Frankel J, Wilén J, Hansson Mild K. Assessing Exposures to Magnetic Resonance Imaging's Complex Mixture of Magnetic Fields for In Vivo, In Vitro, and Epidemiologic Studies of Health Effects for Staff and Patients. Frontiers in public health. 2018:6():66. doi: 10.3389/fpubh.2018.00066. Epub 2018 Mar 12 [PubMed PMID: 29594090]
Cooley CZ, Stockmann JP, Armstrong BD, Sarracanie M, Lev MH, Rosen MS, Wald LL. Two-dimensional imaging in a lightweight portable MRI scanner without gradient coils. Magnetic resonance in medicine. 2015 Feb:73(2):872-83. doi: 10.1002/mrm.25147. Epub 2014 Mar 25 [PubMed PMID: 24668520]
Abd-Ellah MK, Awad AI, Khalaf AAM, Hamed HFA. A review on brain tumor diagnosis from MRI images: Practical implications, key achievements, and lessons learned. Magnetic resonance imaging. 2019 Sep:61():300-318. doi: 10.1016/j.mri.2019.05.028. Epub 2019 Jun 5 [PubMed PMID: 31173851]
Booth TC, Wiegers EC, Warnert EAH, Schmainda KM, Riemer F, Nechifor RE, Keil VC, Hangel G, Figueiredo P, Álvarez-Torres MDM, Henriksen OM. High-Grade Glioma Treatment Response Monitoring Biomarkers: A Position Statement on the Evidence Supporting the Use of Advanced MRI Techniques in the Clinic, and the Latest Bench-to-Bedside Developments. Part 2: Spectroscopy, Chemical Exchange Saturation, Multiparametric Imaging, and Radiomics. Frontiers in oncology. 2021:11():811425. doi: 10.3389/fonc.2021.811425. Epub 2022 Feb 28 [PubMed PMID: 35340697]
Rodríguez-Porcel F, Hughes I, Anderson D, Lee J, Biller J. Foster Kennedy Syndrome Due to Meningioma Growth during Pregnancy. Frontiers in neurology. 2013:4():183. doi: 10.3389/fneur.2013.00183. Epub 2013 Nov 11 [PubMed PMID: 24273529]
Bouffet E, Jouvet A, Thiesse P, Sindou M. Chemotherapy for aggressive or anaplastic high grade oligodendrogliomas and oligoastrocytomas: better than a salvage treatment. British journal of neurosurgery. 1998 Jun:12(3):217-22 [PubMed PMID: 11013683]
Armstrong TS, Ying Y, Wu J, Acquaye AA, Vera-Bolanos E, Gilbert MR, Brown PD, Vardy J, Chung C. The relationship between corticosteroids and symptoms in patients with primary brain tumors: utility of the Dexamethasone Symptom Questionnaire-Chronic. Neuro-oncology. 2015 Aug:17(8):1114-20. doi: 10.1093/neuonc/nov054. Epub 2015 Apr 9 [PubMed PMID: 25862766]
Schrell UM, Rittig MG, Anders M, Kiesewetter F, Marschalek R, Koch UH, Fahlbusch R. Hydroxyurea for treatment of unresectable and recurrent meningiomas. I. Inhibition of primary human meningioma cells in culture and in meningioma transplants by induction of the apoptotic pathway. Journal of neurosurgery. 1997 May:86(5):845-52 [PubMed PMID: 9126901]
Level 3 (low-level) evidenceLiu B, Yu Y, Liu W, Deng T, Xiang D. Risk Factors for Non-arteritic Anterior Ischemic Optic Neuropathy: A Large Scale Meta-Analysis. Frontiers in medicine. 2021:8():618353. doi: 10.3389/fmed.2021.618353. Epub 2021 Oct 4 [PubMed PMID: 34671609]
Level 1 (high-level) evidenceShumway CL, Patel BC, De Jesus O. Neuromyelitis Optica (NMO, Devics Disease). StatPearls. 2023 Jan:(): [PubMed PMID: 34283474]
Petramfar P, Hosseinzadeh F, Mohammadi SS. Pseudo-Foster Kennedy Syndrome as a Rare Presentation of Vitamin B12 Deficiency. Iranian Red Crescent medical journal. 2016 Jun:18(6):e24610. doi: 10.5812/ircmj.24610. Epub 2016 May 14 [PubMed PMID: 27621919]
Hussein MR, Baidas S. Advances in diagnosis and management of oligodendroglioma. Expert review of anticancer therapy. 2002 Oct:2(5):520-8 [PubMed PMID: 12382520]
Level 3 (low-level) evidenceYeh SA, Lee TC, Chen HJ, Lui CC, Sun LM, Wang CJ, Huang EY. Treatment outcomes and prognostic factors of patients with supratentorial low-grade oligodendroglioma. International journal of radiation oncology, biology, physics. 2002 Dec 1:54(5):1405-9 [PubMed PMID: 12459363]
Level 2 (mid-level) evidenceVaquero J, Zurita M, Morales C, Coca S. Prognostic significance of tumor-enhancement and angiogenesis in oligodendroglioma. Acta neurologica Scandinavica. 2002 Jul:106(1):19-23 [PubMed PMID: 12067323]